Related references
Note: Only part of the references are listed.Optical Coherence Tomography Comparison of Percutaneous Coronary Intervention Among Plaque Rupture, Erosion, and Calcified Nodule in Acute Myocardial Infarction
Amir Kh. M. Khalifa et al.
CIRCULATION JOURNAL (2020)
Dose-dependent INhibitory effect of rosuVastatin In Japanese patienTs with Acute myocardial infarcTION on serum concentration of matrix metalloproteinases - INVITATION trial
Koichiro Fujisue et al.
JOURNAL OF CARDIOLOGY (2018)
Association of NF-κB and AP-1 with MMP-9 Overexpression in 2-Chloroethanol Exposed Rat Astrocytes
Tong Wang et al.
CELLS (2018)
Metalloproteinases in atherosclerosis
Jason L. Johnson
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Local Matrix Metalloproteinase 9 Level Determines Early Clinical Presentation of ST-Segment-Elevation Myocardial Infarction
Tsuyoshi Nishiguchi et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma
Pierre Kunz et al.
BMC CANCER (2016)
Simvastatin induces NFκB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells
Ying-Jung Chen et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Translating Koch's Postulates to Identify Matrix Metalloproteinase Roles in Postmyocardial Infarction Remodeling
Rugmani Padmanabhan Iyer et al.
CIRCULATION RESEARCH (2014)
Matrix metalloproteinase levels in chronic thoracic aortic dissection
Xiaoming Zhang et al.
JOURNAL OF SURGICAL RESEARCH (2014)
Correlation between the severity of coronary artery lesions and levels of estrogen, hs-CRP and MMP-9
Changlei Guo et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2014)
Dose-Dependent Effect of Rosuvastatin in the Regulation of Metalloproteinase Expression
Paolo Sapienza et al.
ANNALS OF VASCULAR SURGERY (2011)
Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure
Dimitris Tousoulis et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)
Enhanced cardiac production of matrix metalloproteinase-2 and-9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction
Satoshi Yasuda et al.
CLINICAL SCIENCE (2007)
Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction
DR Wagner et al.
JOURNAL OF CARDIAC FAILURE (2006)
Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction
T Matsunaga et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction
R Nakaya et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Serum matrix metalloproteinase-9 is elevated in men with a history of myocardial infarction
J Renko et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2004)
Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis
Y Noji et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2001)
Share Paper
